BMP2 Regulation of Periosteal Function
BMP2 骨膜功能调节
基本信息
- 批准号:10627170
- 负责人:
- 金额:$ 6.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2022-11-08
- 项目状态:已结题
- 来源:
- 关键词:Anabolic AgentsAntibodiesAreaBMP2 geneBone GrowthBone SurfaceBone TransplantationCell physiologyDefectDevelopmentEnsureExcisionExhibitsExtracellular MatrixFailureFractureGrantGrowthInjuryKnowledgeLeadLengthLifeMediator of activation proteinMolecularMusOperative Surgical ProceduresOsteogenesisOutcomePathological fracturePathway interactionsPatientsPatternPeriosteal CellPeriosteumPhysiologicalPopulationProceduresProductionPublishingRegenerative capacityRegulationRoleSignal TransductionTestingTimeTissuesTraumaVisitWeight-Bearing stateWidthWorkbonebone fracture repairbone repairbone strengthcortical bonedisabilityhealinglong bonenovel therapeuticspostnatalpreventrepairedself-renewalstemstem cellstargeted agenttranscriptome sequencingtumor
项目摘要
Abstract
The periosteum, a highly specialized tissue microenvironment on the outer surface of bone, has a key role in
ensuring the survival and self-renewal of a unique population of resident stem/progenitor cells that are
responsible for appositional bone formation and fracture repair. Injuries that disrupt periosteal function are
common, with 12-15 million fractures occurring yearly in the US that lead to 18 million doctor’s visits and result
in 60 million workdays lost. Although most fractures heal successfully, due in large part to the innate
regenerative capacity of the periosteum, healing is slow and ineffectual (nonunion) for more than 5% of
patients, and failure to heal can be as high as 10% for fractures that occur in weight-bearing long bones that
are crucial for mobility. Recalcitrant fractures are challenging to treat and current therapies produce
unpredictable outcomes, leaving almost 600,000 patients each year with significant disability. Unpredictability
in healing is compounded for procedures that aim to replace large areas of bone lost during trauma or tumor
resection and require bone grafting; almost half of the 500,000 bone grafting surgeries performed each year
fail over time, due in large part to the absence of live periosteal cells that orchestrate the new bone formation
needed to successfully unite the graft to the host bone. Our published work identifies BMP2 as a potent
physiological regulator of periosteal function. Mice lacking BMP2 expression in Prx1+ stem/progenitor cells
exhibit severe defects in all known periosteal activities. In the absence of BMP2, bones fail to grow in width
proportional to their growth in length, creating structural instability that results in spontaneous fracture; once
fractured, the periosteum fails to initiate repair and cannot support bone graft incorporation. In addition,
treatment with anabolic agents such as intermittent PTH or anti-sclerostin antibody fail to stimulate cortical
bone formation in the absence of periosteal BMP2. As such, we hypothesize that the dynamic
spatio/temporal expression pattern of Bmp2 within the periosteal niche constitutes an essential
mechanism determining active versus quiescent states of the periosteum throughout postnatal life. We
propose 3 aims to test this hypothesis. In Aim 1, we will validate the functional role of pathways identified in a
recently completed periosteum RNAseq as downstream mediators of BMP2 signaling during appositional
growth and fracture repair. In Aim 2, we will examine the requirement for BMP2 resident in the ECM of the
periosteal niche versus BMP2 produced by periosteal cell during appositional bone growth. In Aim 3, we will
determine if increasing endogenous BMP2 production by periosteal cells is beneficial for periosteal function.
Completion of these studies will result in a more in depth understanding of the cellular and molecular
mechanisms coordinated by BMP2 signaling in periosteal stem/progenitor cells, and should lead to the
development of novel therapies for enhancing bone repair. Knowledge gained through this proposal also has
the potential to increase the utility of anabolic agents targeted to the periosteum to prevent fractures.
摘要
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Primary Cilia: The New Face of Craniofacial Research.
- DOI:10.3390/biom12121724
- 发表时间:2022-11-22
- 期刊:
- 影响因子:5.5
- 作者:
- 通讯作者:
A periosteum-derived cell line to study the role of BMP/TGFβ signaling in periosteal cell behavior and function.
- DOI:10.3389/fphys.2023.1221152
- 发表时间:2023
- 期刊:
- 影响因子:4
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vicki Rosen其他文献
Vicki Rosen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vicki Rosen', 18)}}的其他基金
The role of ALK4 signaling in skeletal homeostasis and pathogenesis
ALK4 信号传导在骨骼稳态和发病机制中的作用
- 批准号:
10607071 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
2020 Bones and Teeth Gordon Research Conference and Gordon Research Seminar
2020年骨骼与牙齿戈登研究会议暨戈登研究研讨会
- 批准号:
9913185 - 财政年份:2020
- 资助金额:
$ 6.4万 - 项目类别:
Role of the first secreted tyrosine kinase in bone development, homeostasis, and repair.
第一个分泌型酪氨酸激酶在骨发育、稳态和修复中的作用。
- 批准号:
8884704 - 财政年份:2015
- 资助金额:
$ 6.4万 - 项目类别:
Role of the first secreted tyrosine kinase in bone development, homeostasis, and repair.
第一个分泌型酪氨酸激酶在骨发育、稳态和修复中的作用。
- 批准号:
9035363 - 财政年份:2015
- 资助金额:
$ 6.4万 - 项目类别:
Role of the first secreted tyrosine kinase in bone development, homeostasis, and repair.
第一个分泌型酪氨酸激酶在骨发育、稳态和修复中的作用。
- 批准号:
9241348 - 财政年份:2015
- 资助金额:
$ 6.4万 - 项目类别:
Adult Bone Mass Regulation by Type 2 BMP Receptors
2 型 BMP 受体对成人骨量的调节
- 批准号:
9260765 - 财政年份:2014
- 资助金额:
$ 6.4万 - 项目类别:
Adult Bone Mass Regulation by Type 2 BMP Receptors
2 型 BMP 受体对成人骨量的调节
- 批准号:
8692188 - 财政年份:2014
- 资助金额:
$ 6.4万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 6.4万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 6.4万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 6.4万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 6.4万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 6.4万 - 项目类别: